DEA Eases Requirements for Natural Cannabis-derived Drug Research

The U.S Drug Enforcement Administration (DEA) on Wednesday relaxed some restrictions on research evaluating cannabidiol, an extract of the marijuana plant, for medicinal use.

 

The modifications will ease some requirements imposed by the Controlled Substances Act on possession of cannabidiol (CBD) for a specific U.S. Food and Drug Administration (FDA)-approved research protocol, the DEA said.

So far, researchers who expanded the scope of their studies and required more CBD than initially approved had to request, in writing, for a modification to their DEA research registrations.

The modification had to be sanctioned by the FDA and DEA, potentially holding up research.

As part of the changes announced on Wednesday, a previously registered CBD clinical researcher who is granted a waiver can readily modify the protocol and continue research seamlessly. 

The changes are effective immediately, the DEA said.

Drug policy reformers have been urging the...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.